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                   Abstract 
 
Pramanicin (PMC) is a novel anti-fungal agent. In this study, among eight analogues screened by 
MTT cell proliferation assay for their potential cytotoxic effect on HCT116 colon cancer cells, 
Pramanicin-A and Pramanicin-F were found to be the most effective candidates at the 
concentration of 25uM and 75uM respectively. Flow-cytometric analyses with Annexin-V 
staining and M30 apoptosense eliza assay confirmed that PMC-A is a more effective apoptotic 
agent compared to PMC-F, thus PMC-A was selected for further studies. Moreover, no 
difference in cytotoxicity was observerved in puma and bax defficient cell lines, therefore further 
studies were conducted with HCT116 wild type cells.  In order to get insight into the mechanism 
of apoptotic response by PMC-A, we followed MAP kinase pathways with using specific MAPK 
antibodies and inhibitors. Our immunoblotting data reveals that PMC-A induced the 
activation/phosphorilation of c-jun terminal kinase (JNK), p38 and extracellular signal-regulated 
kinases (ERK1/2) in different time kinetics. Inhibition of caspase-3, and caspase-9 with their 
specific inhibitors prevent apoptosis. Interestingly inhibition of JNK and p38 
activations/phosphorilations potentiated the apoptotic response. These data indicate that PMC-A 
induced apoptosis is mediated by caspase dependent pathways, activation of JNK and p38 but not 
ERK 1/2 may have a pro-survival role.Finally our data from flow-cytometric and flourometric 
analyses with D2CDF-DA staining revealed induction of reactive oxygen species (ROS) acting 
as second messengers which may activate MAPK signaling pathways as well as other signaling 
pathways in apoptotic response of cells to PMC-A at early (1h, 2h) and late (24h) time points.     
 v 
                ÖZET 
Pramanicin yeni bulunan bir anti-fungal ajandır. Bu çalışmada, HCT116 kolon kanseri 
hücrelerinde, sekiz analoğun MTT proliferasyon yöntemi kullanılarak sitotoksik potansiyelleri 
taranmıştır. PMC-A (25uM) ve PMC-F (75uM), bu analoglar içerisinde en güçlü potansiyele 
sahip ajanlar olanlar olarak bulunmuştur. Flowsitometrik ve M30 apoptosense eliza yöntemine 
dayanarak elde edilen sonuçlar PMC-A’ nın PMC-F’ e gore daha güçlü bir apoptotic ajan 
olduğunu ortaya koymaktadır. Bu sebeple çalışmanın tümünde PMC-A kullanılmıştır. Bununla 
birlikte bax ve puma knock-out hücreler ile yapılan çalışmalarda, sitotoksisite bakımından 
anlamlı bir fark bulunamamış ve çalışmanın tamamında normal tip HCT116 hücreleri 
kullanılmıştır. Daha ileriki aşamada PMC-A’ nın apoptotic etkisinin moleküler düzeyde 
araştırılması için, MAPK yolakları spesifik antikor ve inhibitorler kullanılarak araştırılmıştır. 
Yapılan immunoblot çalışmalarında PMC-A’ nın JNK, p38 ve ERK1/2 üzerinde farklı zaman 
kinetiklerine uygun olarak aktive edici etkisinin olduğu ortaya çıkarılmıştır. Kaspaz-3 ve Kaspaz-
9’ un spesifik inhibitorler ile baskılanması apoptozu başarılı bir biçimde durdururken, tam ters bir 
etki ile JNK ve p38 aktivasyonlarının inhibisyonları apoptozu potansiyelize ederek daha fazla 
hücrenin ölmesine yol açmıştır. Bu sonuçlar göstermektedir ki, PMC-A kaynaklı apoptoz Kaspaz 
yolaklarına bağlı iken, JNK ve p38’ in içerisinde bulundukları yolaklar hücrenin yaşaması ile 
ilişkili yolaklar ile ilişkili olabilir. Bununla birlikte ERK1/2’ nin inhibisyonu ne apoptoz nede sağ 
kalım üzerinde herhangi bir etki oluşturmamaktadır. Son olarak, çalışmamızda florometrik ve 
flowsitometrik D2CDF-DA boyama yöntemi kullanılarak yapılan çalışmalarda, PMC-A’nın 
MAPK yolakları gibi birçok yolağı aktive edebilen veya kendi başına bir ikincil haberci gibi 
davranarak apoptoz oluşumunda rol alabilen reaktif oksijen ürünlerinin oluşumuna aracılık ettiği 
hem erken (1saat, 2saat) hemde geç zaman (24saat) dilimlerinde ortaya konulmaktadır.                
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1         INTRODUCTION 
Pramanicin (PMC) is a recently discovered antifungal molecule with an aliphatic side chain and a 
polar head group. It was synthesized in Stagonospora Sp. cultured in liquid medium. After seven 
days of culturing, the cultures were centrifuged and the supernatant extracted with methyl ethyl 
ketone. After concentration, the organic extracts were purified by column chromatography (SiO2, 
10% MeOH/EtOAc). Final purification was done with MPLC on a Merck LOBAR RP-8 column 
in MeOH–H2O (70:30), finally giving approx. 75 mg of pramanicin, as previously described in 
[1]. PMC has ten different analogues with different molecular structures as shown in Figure 1.1. 
Minimal inhibitory concentrations of 20-100uM is found effective in growth-inhibition on fungal 
organisms. It has been previously shown that PMC increases cytosolic calcium concentration and 
induces cell death in endothelial cells [2]. Also Pramanicin was recently found as an apoptotic 
agent which acts through MAPK pathways and activates specific caspases in jurkat leukemia 
cells [16]. Targeting apoptotic machinery components and restoring apoptotic regulators that are 
impaired is nowadays seem the best approach for treating cancer. Day by day knowlegde of 
mechanisms of the apoptosis and how its regulated is being increased, many of the novel 
approaches to target the apoptotic cascades are being tried on many cancer therapies in vivo and 
in vitro. Many of these are still in preclinical stage, some of them are showing a good potential 
and are progressing into the clinical stage, [3], In cancer therapy we are using very powerful 
weapons such as chemotherapy and radiotheraphy, many drugs are investigated and produced for 
killing cancer cells by targeting the apoptotic machinery, although many patients could take 
advantage of these chemotherapautics and their cancer could be regressed by using those drugs, 
but it must not be forgotten that all those drugs have many side-effects including forming new 
cancer cells within body. Maybe the worst part of the chemotherapy is effected normal 
proliferative cells such as intestine and epidermal cells in body just because of unspecificity of 
the cancer drugs. Now it seems that we are quite far away from finding a drug that is only 
specific to cancer cells. But in future, in the light of the scientific advances, of course we will 
have better drugs to fight against the cancer without disturbing the normal and functional cells 
within body. Apoptosis is mediated by the signaling cascades, there are two well-characterized 
apopotic pathways, one of them is initiated through the interactions of the surface death receptors 
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and their ligands and other one is related to changes in internal cellular integrity. These two 
distinct pathways generally activate the caspases and cause apoptosis, briefly cleavage of initiator 
caspases and the effector caspases has been defined the typical features of apoptosis in response 
to death receptor activation or intracellular insult. The apoptotic machinery highly depends on the 
finaly tuned protein-protein interactions and protein modifications after intrinsic and extrinsic 
pathways activation. Most of the chemotherapeutics target the regulator proteins of the apoptotic 
machinery and give us an opportunity to eliminate the cancer cells from the body. Intrinsic and 
extrinsic pathways and the regultor proteins have been broadly defined [4]. One of the apoptosis 
mediating signaling pathway is defined mitogen-activated protein kinases (MAPK) pathway. In 
mammals there are three different groups of mitogen-activated protein kinases (MAPKs), many 
types of stress can activate c-Jun N-terminal kinase and p38 MAPKs like UV radiation, growth 
factor withdrawal and pro-inflammatory cytokines [5,6]. After activation through a dual 
tyrosine/threonine phosphorilation mechanism by their upstream kinases, p38 and JNK 
phosphorilate many transcription factors like c-Jun, p53 and ATF-2 [7]. JNK and p38 kinases 
have been shown to function pro-apoptotic or anti-apoptotic in many different studies [8, 9, 10, 
11]. Even if apoptosis is not seen in response to many stimuli, JNK and p38 MAP kinases 
activations were shown [12, 13]. The other MAP kinase called extracellular signal regulated 
kinases (ERK1/2, p42/p44 kinases) is activated by growth factors and mitogenic stimuli [14, 15]. 
There have been intensive work on MAP kinases and they were reported that they can function in 
response to many stimuli and they can be involved pro-apoptotic and anti-apoptotic pathways that 
decide cells to go apoptosis or to survive. Their function is determined by cell type, stimuli 
origin, duration, initial magnitude, further amplification of the activated signal trunsduction 
pathway, co-activation of other signaling pathways. Also they have reported that they can be also 
activated without apoptosis in response to many stimuli. Thus the activation patterns of MAP 
kinases must be carefuly evaluated in their pro-/anti-apoptotic properties in the light of the above 
parameters [12, 13, 16]. Oxidative stress is also one of the activator of the molecular signaling 
cascades and apoptotic machinery in the cells. Oxidative stress can be described as an increase in 
the reduction potential or a large decrease in reducing capacity of the cellular redox couples. 
Production of reactive oxygen species (ROS) which include free radicals and peroxides can be so 
harmful for the cells. However some of the ROS species are less reactive then others, they can be 
easily converted to more reactive and dangerous species by oxidoreduction reactions with 
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transition metals. These highly active ROS species can cause extensive cellular demage. In 
animals, ROS may influence cell proliferation, cell death, and expressions of some ROS related 
genes, activation of several signling pathways, acivation of cellular signalig cascades such as 
those involving mitogen activated protein kinases. Most of the ROS species can be produced by 
aerobic metabolism at a low level from mitochondria and can be easily repaired by some of the 
spesific mechanism in the cells. In cells, there are enzymes and antioxidants which preserve the 
cellular redox environment and maintain the reduced state through a constant input of metabolic 
energy [17]. There has been a broad research on oxidative stress and its functions to activate the 
molecular signaling cascades. Oxidative stress is also one of the major causes of apoptosis which 
is involved many diseases like diabetes and neurodegenerative diseases. It is so important to 
understand the mechanism of oxidative stress to eliminate the problems which threat the human 
health. 
 
 
 In this study, we investigated three major topics, Potential apoptotic effect of PMC-A in 
HCT116 cells, activation of MAPK pathway by PMC-A and finally induction of ROS production 
in response to PMC-A treatment. For this purpose, here we will focus on the apoptosis to 
understand the signaling mechanisims mediating this event. Then one of the most important 
apoptosis mediating pathway, MAPK pathway will be reviewed, finally reactive oxygen species 
production mechanisms and its relationship with MAPK pathway and apoptosis which could be 
mediated by MAPK will be discussed. 
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Figure 1.1 PMC and its analogues (PMC, PMC-A, PMC-B, PMC-C, PMC-D, PMC-F, 
PMC-G, PMC-H, PMC-I, PMC-J) 
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       2  BACKGROUND 
           2.1 Apoptosis 
 
 Apoptosis is the Greek word for “falling off” or “dropping off” and describes the specific 
and unique changes in cells [18] . Apoptosis, first described by Kerr et al in 1972 [19], It is now 
seen as a potential target for cancer therapy during the past 30 years. When tumor cells are 
failured to undergo apoptosis, they progress into cells which have malignant potential and 
chemotherapeutic resistance. The process of apoptosis is a dynamic interplay of several 
molecules with upregulatory and downregulatory properties that is largely dependent on the cell 
type and the form of insult. No single factor in the machinery of apoptosis operates in isolation. 
Activation or inactivation of a single component alters the fate of the cell and lead them to 
programmed cell death named apoptosis. The typical executioners of apoptosis are the proteolytic 
enzymes called cysteinyl aspartate-specific proteases. Caspases are divided into two groups, the 
first one is initiator caspases (8 and 10), characterized by a long N-terminal, and the other is 
execution caspases (3, 6, and 7), characterized by a short N-terminal. Caspases 3, 6, and 7 are 
activated by way of two classical pathways: the extrinsic (death receptor) and the intrinsic 
(mitochondrial) (Fig. 2.1.1). In the extrinsic (death-receptor) pathway, binding of tumor necrosis 
factor (TNF), TNF-related apoptosis-inducing ligand treatment (TRAIL), or Fas ligands to their 
receptors, in association with adaptor molecules such as Fas-associated death domain (FADD) or 
TNF receptor–associated death domain, leads to cleavage and activation of initiator caspase 8 and 
10, after that cleavage and activation of executioner caspases 3, 6, and 7, mediate apoptosis 
[20,21] . In the intrinsic (mitochondrial) pathway, proapoptotic proteins results in a net increase 
of free cytosolic cytochrome c. Once released, cytochrome c interacts with apoptosis-activating 
factor-1 (Apaf-1), adenosine triphosphate, and procaspase 9 to form the apoptosome. The 
apoptosome cleaves caspase 9 and activate it, which in turn caspases 3, 6, and 7 are activated, 
thus apoptosis is stimulated [22].  The relative permeability of the mitochondrial membrane to 
cytochrome c is determined by the ratio of proapoptotic and antiapoptotic mediators. When 
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proapoptotic molecules BAX and Bcl-2 antagonist/killer (Bak) (see Table 2.1.1 summary of 
molecules in the same family with similar functions) are translocated from the mitochondrial 
intermembrane, they cause a net increase of cytochrome c which in turn interacts with the 
apoptosome. The effect of these proapoptotic molecules is mediated by either altering 
mitochondrial membrane permeability; by coupling of proapoptotic molecules with antiapoptotic 
factors (ie, Bcl-2, Bcl-xL, and Mcl-1), thereby neutralizing their antiapoptotic actions; or a 
combination of these [23]. Therefore the relative ratio of proapoptotic and antiapoptotic 
mediators determines the relative amount of cytochrome c available to interact with the 
apoptosome. Release of second mitochondrial-derived activator (Smac/DIABLO) and 
Omi/HTRA-2 from the mitochondrial intermembrane neutralizes the actions of inhibitors of 
apoptosis (IAPs) such as cIAP1, cIAP2, and X chromosome–linked inhibitor of apoptosis 
(XIAP), thus causing a net stimulus of downstream caspases [24] . Synthesis and activation of 
IAPs are modulated by the transcription factor nuclear factor kappa beta (NF kB), NfkB is found 
in an inactive form in the cytoplasm bound to Ik B. Stimulation of apoptosis causes 
phosphorylation and subsequent degradation of I kB which in turn NF kB is freed. After that 
NFkB translocates into the nucleus and it mediates transcriptinal activation of IAPs [25] . For 
induction of apoptosis by chemotherapeutic agents, mitochondrial pathway is relatively more 
important than the death-receptor pathway. in particular, caspase 9–eficient cells and Apaf-1–
negative thymocytes are resistant to chemotherapeutic agents, but induction of apoptosis can be 
mediated by Fas, TRAIL, or TNF (the death- receptor pathway) [26,27] . In contrast, embryonic 
fibroblast cells are FADD negative and caspase 8 negative which are resistant to apoptosis in 
response to death receptor pathway activation, yet they are still sensitive to cytotoxic drugs 
[28,29] . The death-receptor pathway, conversily, appears to be more important than the 
mitochondrial pathway in rendering cancer cells survival advantage by providing immune 
privilege. The mitochondrial and death-receptor pathways have crosstalks at various levels. 
Activation of caspase 8 causes stimulation of BH3-interacting domain death agonist, which in 
turn it leads to release of cytochrome c and apoptosome formation (in type II cells) [30] . 
Similarly, downstream stimulation of caspase 6 may in turn activate caspase 8 [31]. Both 
pathways can be regulated by heat shock proteins (HSP), which can have proapoptotic and 
antiapoptotic features [32]. Antiapoptotic HSP include HSP27, which inhibits release of 
cytochrome c, and HSP70 and HSP90, which bind to Apaf-1, thereby inhibiting the apoptosome. 
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Proapoptotic HSP60 and HSP10 directly stimulate caspase3 [33]. Other mechanisms of apoptosis 
which are independent of the caspase cascade have been described. The mediators involved are 
still not known well and have not been characterized, but they may involve proteases, apoptosis-
inducing factors (AIF), endonuclease G, calpains, and cathepsins [34]. 
 
   Figure 2.1.1 Apoptotic molecules with similar functions [35]. 
 
  
Figure 2.1.2 Mechanisms of apoptosis. The death receptor (extrinsic) and mitochondrial          
(intrinsic) pathway of apoptosis. (Arrow) Stimulatory effects. (Dashed line) Inhibitory     
effects[35]. 
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        2.2 Functions of MAP Kinases  
 
 Mitogen-activated protein kinases (MAPKs) are a family that control various cellular 
physiological functions of cells in number of organisms ranging from yeast to mammals, they 
highly conserved serine/threonine sites to be phosphorilated, these phosphorilations regulate their 
activities in response to various stimuli. As shown in Table 2.2.1 Gene-targeting studies have 
revealed their functions in vivo. In particular, embryos deficient in extracellular signal-regulated 
kinase (ERK2) 2 lack mesoderm differentiation and placental angiogenesis. Knockout mice of c-
Jun amino-terminal kinases have revealed roles for these kinases in neural apoptosis and 
activation/differentiation of T cells. Deletion of p38α MAPK results in angiogenic defects in the 
placenta and peripheral vessels. ERK5-deficient embryos are embryonic lethal due to defects in 
angiogenesis and cardiovascular development. Also disease pathogenesis MAPKs are having a 
significant role, especially in cancer, thus working with MAPKs and reveal their functions in 
both cancer and healthy cases are so important to understand the mechanisms related to cancer 
progression and some diseases that MAPKs involved. Mitogen-activated protein kinases 
(MAPKs) are a family of highly conserved kinases. Serine and threonine residues of target 
protein substrates are phosphorylated by specific MAPKs and number of cellular activities 
including gene expression, mitosis, cell movement, metabolism, cell survival and apoptosis are 
regulated by them. MAPKs are one part of a three tiered cascade composed of a MAPK kinase 
(MAPKK, MKK, or MEK) and a MAPKK kinase (MAPKKK or MEKK). In mammals, at least 
four distinct groups of MAPKs have been recognized. Two extracellular signal regulated kinases 
(ERK1/2) are phosphorylated by specific MAPKKs, MKK1 and MKK2. MKK1/2 are known to 
be activated by upstream MAPKKKs such as RAF proteins whose functions are regulated by 
many growth factors and the proto-oncogene named RAS. In response to various stress stimuli, 
three JUN-amino-terminal kinases (JNK1/2/3) and four p38 protein kinases (p38α/β/γ/δ) are 
phosphorylated by MKK4/7 and MKK3/6, respectively. A number of MEKKs for JNKs and p38 
protein kinases have been identified, some of which activate both JNK and p38 cascades [6,36]. 
Detailed signalling cascades for MAPK are reviewed in [37]. 
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          2.2.1 Extracellular-Regulated Kinase 1,2(ERK) Pathway 
 
 
Mitogens and growth factors are activating mainly the ERK pathway (A-Raf, B-Raf, Raf-
1MEK1, 2ERK1,2). This pathway has been related to cell growth, cell proliferation, and 
survival. Receptor-mediated activation of the small G-protein, Ras, is activating most of the ERK 
pathway signals. Ras is a membrane-bound protein activated by the exchange of GDP that is 
bound to Ras to GTP. The activation of Ras, thus requires the relations with proteins responsible 
for initiating GDP/GTP exchange to the membrane. Activated Ras, then recruits cytoplasmic Raf 
(MAPKKK) to the cell membrane for its activation. There are three mammalian serine/threonine 
Raf kinases: A-Raf, B-Raf, and Raf-1 (named as C-Raf). Gene knock-out studies in mice have 
showed that, these proteins have distinct biological functions. All three Raf proteins share the 
same downstream MAPKK substrate mitogen activated protein kinase kinases 1,2 (MEK1,2). 
MEK1,2 is activated by dual phosphorylation on two serine residues by Raf proteins. In addition, 
recent studies have shown evidence for Ras/Raf-independent activation of MEK1,2 by both p21 
kinase (PAK) and MEKK1–3 kinases. MEK1 and MEK2 are named dual-specificity kinases and 
they share 80% amino acid sequence identity. ERK1,2 is activated by MEK1,2, specifically by 
phosphorylating a tyrosine and a threonine residue, separated by a glutamate residue (TEY) 
within the activation loop of the ERK protein (38,39). ERK1 and ERK2 share 85% amino acid 
identity and they are ubiquitously expressed. Active ERK1,2 can translocate into the nucleus, 
immediately after it activates various transcription factors, such as c-Fos, ATF-2, Elk-1, c-Jun, c-
Myc, and Ets-1 shown in Figure 2.2.1.1 Activated ERK1,2 can also phosphorylate cytoplasmic 
and nuclear kinases, for example MNK1, MNK2, MAPKAP-2, RSK, and MSK1,2 (38,39). In 
mouse fibroblasts, serum-elicited ERK1,2 activation was originally shown to be required for 
proliferation and transformation. Moreover, it was shown that in human fibroblasts and 
mammary epithelial cells, Ras-mediated activation of Raf was identified as one of the 
requirements for transformation [40,41]. It was shown that, mutations of B-Raf, that increase the 
activity of the MEK1,2- ERK1,2 pathway, were revealed in several malignancies. and expression 
of such mutants in NIH3T3 cells lead to transformation. In particular, the B-Raf mutation V600E 
was detected in 70% of malignant melanomas, strongly supporting a positive role for ERK 
pathway activation in melanoma progression[42]. In addition to proliferation, ERK1,2-mediated 
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signaling also has a pivotal role mediating cell survival. For example, activated alleles of MEK1 
and MEK2 mediate cell survival without survival factors. Dominant interfering mutants of MEK1 
and MEK2 alleles disrupt cell survival signaling(reviewed in 43). Bonni A. Et al.(1999) proposed 
that ERK1,2-dependent survival signaling has been found to be mediated mainly through 
activation of RSK kinase. Active RSK phosphorylates, and thereby inactivates, the proapoptotic 
protein BAD. RSK can also activate the transcription factor CREB, which promotes cell survival 
through transcriptional up-regulation of antiapoptotic Bcl-2, Bcl-xL, and Bcl-1 proteins[44]. 
Moreover, Fas mediated apoptosis can be suppressed by ERK1,2 activity through inhibiting the 
formation of the death-inducing signaling complex (DISC) [45]. The utility of MEK-ERK 
pathway inhibition in cancer therapy was originally demonstrated by suppression of colon tumor 
growth in a mouse model by chemical inhibition of MEK1,2 [46]. In many other studies such as 
work by Rosen and collaborators using chemical inhibition of the B-Raf V600E chaperone 
Hsp90, have further proposed that MEK-ERK pathway inhibition as an attractive opportunity for 
cancer therapy. 
 
 
 
                  2.2.2 C-jun N-Terminal Kinase (JNK) Pathway 
 
 
 
C-Jun N-terminal kinase (JNK) pathway is mainly activated by cytokines and cellular stress. 
JNKs are acrivated by these stimuli through several upstream kinases (MAPKKKs), such as 
ASK1, HPK1, MLK-3, MKKK1–4, TAK-1, and TPL-2 [47,48]. MAPKKs, MKK4 and MKK7 
are needed for JNKs fully activation. Both MKK4-/- and MKK7-/- mice are embryonic lethal 
[49,50], but in fibroblasts derived cell culture experiments, MKK4 and MKK7 knockout mice 
revealed that MKK7 mediates JNK inflammatory responses, and both MKK4 and MKK7 are 
crucial for stress-induced JNK activation [49]. Interestingly, a recent study provided evidence of 
an alternative pathway for JNK activation, through reactive oxygen mediated suppression of JNK 
phosphatase activity [51]. Three JNK genes—JNK-1, JNK-2, and JNK-3—are susceptible to 
alternative splicing, resulting in more than 10 JNK isoforms (47,48). As well as all other MAPKs, 
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JNKs activation needs phosphorylation of a tyrosine and a threonine residue, although specificity 
from the other MAPKs is ensured by the separating proline (TPY) within the activation loop of 
the kinase. JNKs has 85% sequence identity and are expressed ubiquitously. JNK pathway 
activity can function in indusing apoptosis, proliferation, or survival, depending on the stimuli 
and cellular conditions. Interestingly, sustained JNK activity is necessary for cellular 
homeostasis, whereas strong stress stimuli in non-transformed cells primarily leads to JNK 
mediated apoptosis. In JNK-knockout mice, the removal of any JNK isoform alone resulted in 
healthy and viable offspring, although some T cell abnormalities were observed in JNK1 and 
JNK2 knock-out mice [47,48]. Double knockout mice, lacking both JNK1 and JNK2, were 
embryonic lethal because of altered apoptosis during brain development (48,52,53). JNK3-/- 
mice showed differences in neuronal apoptosis compared to normal mice [54]. According to 
these findings demonstrate that JNKs isoforms has specific functional differences. The most 
classical JNK substrate is the transcription factor c-Jun, from which JNK derived its name. JNK 
can activate other transcription factors, such as ATF-2, Elk-1, MEF-2c, p53, and c-Myc. JNK 
also has other nontranscriptional substrates, for example the antiapoptotic proteins, Bcl-2 and 
Bcl-xL [47, 48]. 
 
       2.2.3 P38 Pathway 
 
 
The p38 MAPK pathway (MAPKKKs/MKK3,4,6/p38) can be activated by inflammatory 
cytokines, as well as pathogens and by environmental stress, including osmotic stress, ultraviolet 
light, hypoxia and heat shock. p38 MAPK pathway can also be activated by some mitogens, such 
as erythropoietin, colony stimulating growth factor 1, and granulocyte macrophage colony 
stimulating factor [reviewed in 55]. Considering the broad range of signals that can activate the 
p38 MAPK pathway, it is not unexpecting that several MAPKKKs can activate the p38 MAPK 
signaling module and that the specificity of activation may be determined by the stimuli. For 
instance, MTK1 cannot mediate cytokine signaling but can only stress signaling [55]. The p38 
MAPK protein is represented by four isoforms: p38α, p38β, p38γ, and p38δ. Activation of all the 
p38 isoforms is needed dual phosphorylation of at hreonine and a tyrosine within the threonine-
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glycine-tyrosine (TGY) sequence in the activation domain of the kinase [55, 56]. Activated p38 
proteins can activate several transcription factors, such as ATF-2, CHOP-1, MEF-2, p53, and 
Elk-1. Importantly, p38 can also activate other kinases, including MNK1 and MNK2, MSK1, 
PRAK, MAPKAPK-2, and MAPKAPK-3. p38 MAPK pathway activation has a pivotal role for 
apoptosis induction in various cellular models [57-63]. In addition, stress-induced activation of 
p38 was shown that it causes G2/M cell cycle arrest and regulates the cell cycle through 
modulation of p53 and p73 tumor suppressor proteins [64,65]. Conversely,p38 MAPK pathway 
activity has been reported to promote cancer cell growth and survival. For instance, high p38 
MAPK activation has been observed in some cancer types, as compared to their matched controls 
(66-68). p38 MAPK activity also correlated with the invasiveness of several cancer cell lines and 
inhibition of p38 activity reduced their proliferation, survival, and invasion [68]. The molecular 
mechanisms determining whether p38 signaling either promotes or inhibits cell proliferation and 
survival have not been elucidated but it could potentially be depend on the transformation state of 
the cell or could be related to the nature of p38-activating signal. Moreover, the p38 pathway has 
a pivotal role to regulate the expression of many inflammatory molecules, differentiation of 
epidermal keratinocytes, myoblasts, and immune cells, as well as mediates innate immune 
responses [69]. 
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Table 2.2.1 Summary of MAPK knockout phenotypes [6]  
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Figure 2.2.1.1. MAPK signaling pathways. MAPK signaling pathways are organized in 
modular cascades in which activation of upstream kinases by cell surface receptors lead to 
sequential activation of a MAPK module (MAPKKK - MAPKK - MAPK). Shown are the major 
MAPK pathway components and examples of the MAPK pathway target proteins. Target kinases 
are in bold. Dotted lines indicate context-dependent signaling connections between MAPK 
modules [37]. 
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            2.3  Oxidative Stress 
 
Cells have to constantly deal with highly reactive and dangerous oxygen-derived free radicals. 
Defence mechanism against reactive oxygen species (ROS) involves antioxidant molecules and 
the antioxidant enzymes. ROS are generated by aerobic methabolism in cells and they are 
believed that they play a pivotal role in aging and several degenerative diseases. Finding of new 
specific genes and pathways related by oxidants showed us ROS function as a subcellular 
messenger in gene regulatory and signal trunsduction pathways. There are so many examples 
suggest that ROS effects on cellular compartments and regulatory levels shown in Table 
2.3.1[70,71]. Growth factors, cytokines and several ligands can trigger ROS production in 
nonphagocytic cells upon their specific membrane receptors. Thus ROS production can be 
occured in a positive feedback mechanism on signal trunsduction from these receptors since 
intracellular signalling is often induced by ROS or pro-oxidative shift of the intracellular 
thiol/disulfide redox state. The reductive process is depend on the presence of transition metals, 
such as copper and iron, or specific enzymes (certain ozidases, monooxygenase) . This activation 
occurs in several cellular compartments such as mitochondria, microsomes, peroxysomes, and 
cytoplasmic membrane[72-76]. There are specific defense mechanisms called antioxidant defense 
system against the potential of the oxygen toxicity in cells. One of them works up the radical 
chain , inhibiting activation mechanisms. The other one neutralizes the free radicals already 
formed and stops the chain prrogression which involves some of the specific detoxifying 
enzymes, such as superoxide dismutase (SOD) and catalase. Some of the molecules act like a 
suicidal molecules or an anti-oxidant shield  against ROS. Some of these molecules are in lipidic 
phase such like tocopherols, carotenoids, ubiquinones. Other molecules such as ascorbic acid, 
uric acid which are lipophobic are active in hydrated environment. When the defense 
mechanisms of the cells are weakened or excess production of ROS, a state of oxidative stress 
occurs. Thus many targets such as lipids, DNA,proteins are harmed by the radicals[72,77,78].  
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 Table 2.3.1 Protein kinases and transcription factors effected by ROS [70]. 
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                    2.3.1 ROS Generation 
 
 
 Researchers have been interested in ROS for many years in all areas of biology. Originally 
ROS were found as being instrumental for mammalian host defense, and early work led to the 
characterization of the respiratory burst of neutrophils[79] and originally the NADPH oxidase 
complex[79,80], it is now recognized as a primary source of ROS. However, recent works have 
revealed a more widespread and exciting role of ROS: that of key signalling molecules. ROS are 
species of oxygen which are in a more reactive state than molecular oxygen, and by which 
therefore, oxygen is reduced to varying degrees. A primary ROS is superoxide (O2−), which is 
formed by the one electron reduction of molecular oxygen. This is the reaction catalysed by 
NADPH oxidase, with electrons supplied by NADPH[81]. Oxygen's further reduction produces 
hydrogen peroxide (H2O2). This can come from the dismutation of O2−, which can occur 
spontaneously, especially at low pH. However, this reaction can also be catalyzed by SOD 
enzyme family. Therefore, under physiological conditions, once O2− is formed the presence of 
H2O2 becomes almost inevitable. Further reactions may lead to the formation of hydroxyl 
radicals (OH), especially in the presence of metal ions through the Fenton or Haber±Weiss 
reactions[81,82]. Hydroxyl radicals are highly reactive and dangerous, and their halflife is very 
short, they generaly react with the first molecule nearby. In neutrophils, myeloperoxidase 
catalyses the formation of hypochlorous acid (HOCl), while O2− may also react with nitric oxide 
(NO) to form another relatively reactive molecule, peroxynitrite : NO + O−2 → ONOO− 
(peroxynitrite). It thus appears that, following the formation of superoxide anions, a cascade of 
ROS production is likely. Some of these ROS, especially H2O2 , are key signalling molecules, 
while others appear to be extremely detrimental to biological systems, effects that are dependent 
on the concentrations that are perceived by the cells. However, to be considered as a potential 
signalling molecule, ROS must: (a) be produced by a cell when stimulated to do; (b) have an 
action in a cell, either the cell which produces it or a nearby cell; and (c) be removed in order to 
turn off, or reverse, the signal[83]. 
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                                   2.3.2 ROS and Signalling Pathways 
 
 
In many ways, ROS are ideal signalling molecules because of the small size, and they can 
diffuse short distances; there are several mechanisms of their production, some of them are rapid 
and controllable; and cells have several mechanisms for their quick removal. Many studies have 
showed a role for ROS in the induction or inhibition of cell proliferation, in both activation and 
inhibition of apoptosis, and, at higher concentrations, in the induction of necrosis[84-88]. Some 
of the biochemical effects of ROS on cells will be showed in Figure 2.1. It has been shown that 
several enzymes involved in cellular signalling mechanisms are potential targets of ROS. Some 
examples are; Several enzymes which are involved in cell signalling mechanisms are also 
potential targets of ROS. These include guanylyl cyclase [105], phospholipase C [106,107], 
phospholipase A2 [108–109] and phospholipase D [110], the latter again from direct attack of 
cysteine. Ion channels too may be targets [111,112], including calcium channels [113]. Signalling 
mechanisms that respond to changes in the thiol/disulfide redox state includes AP-1 transcription 
factor in human T cells, nuclearfactor κB (NF-κB) transcription factor in human T cells [114], 
control of K+ channel activity in the carotid body [115], human insulin receptor kinase activity 
[116], Src family kinases, JNK and p38 mitogen-activated protein kinase (MAPK) signalling 
pathways [117] and signalling in replicative senescence [118]. 
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      Figure 2.3.2.1 Potential intracellular signaling pathways mediated by NADPH oxidase 
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                        2.3.3  ROS, Gene Expression and Protein Phosphorilation      
        
Reactive oxygen speices are involved in many problems that we face such as aging, degenerative 
diseases, diabetes mellitus. They are produced by all aerobic cells by many ways. Thanks to the 
usage of numerous molecular genetic techniques, expression of a wide range of genes is regulated 
by hydrogen peroxide have now revealed. [89]. It has been reported that the addition of H2O2 (or 
xanthine oxidase/xanthine) stimulated the expression of c-fos and c-myc[90], and increased 
expression of c-jun, egr-1 and JE has also been reported [91,92]. Other examples include 
increased expression of clones identified as fibronectin and p105 co-activator in rat aorta smooth 
muscle cells, as shown by subtractive hybridization [93]. If H2O2 is altering gene expression 
patterns in cells, how is this being achieved? Transcription factors have been shown to be 
activated by H2O2. Schreck et al. [94] showed that H2O2 activates the transcription factor 
nuclear factor-kB (NF-kB). NF-kB usually is in the cytoplasm of the cell in association with an 
inhibitor protein, Ik-B, but addition of H2O2 to cells results in the dissociation of NF-kB from Ik-
B, and translocation of NF-kB to the nucleus. Other transcription factors affected by exogenous 
H2O2 include AP-1, Myb and Ets [95-97]. Reversible protein phospholiration is the one of key 
modulators in cellular signalling, and plays a critical role in many cellular metabolic processes in 
eukaryotes. In particular protein phosphorilation mediates numerous signal trunsduction 
pathways. For the balance of the intracellular signalling environment, protein phosphorilation 
must be reversible, thus phosphatases are involved in the phosphorilation process as well as 
protein kinases are involed in. Cellular target proteins are phosphorilated at specific cellular 
transduction sites(usually serine/threonine or tyrosine residues) by one of the protein kinases and 
the phosphates are removed by a specific phosphatase. ROS production is also an event which 
protein phosphorilations occur. Mitogen activated protein kinases are one of the key elements 
that can be regulated by phosphoilation in response to ROS production both in animals and 
plants, this phosphorilations of MAP kinases leads to gene expressions which regulates the cell 
response[98-101]. H2O2 is one of the rective oxygen species and H2O2 has been shown to 
inhibit phosphatases, probably by the direct oxidation of cysteine in the active site of these 
enzymes [102-103]. The JAK/STAT (Janus kinase/signal transducers and activators of 
transcription) pathways in animal cells are also activated by H2O2 [104], these findings suggest 
that H2O2 may transduce its message into the nucleus by at least two signal transduction 
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pathways. H2O2 may be sythesized endogenously in certain cell types as a response to activation 
by specific cytokines or growth factors. this endogenous H2O2  then plays as a second messenger 
role to stimulate protein kinase cascades related to inflammatoryvgene expression, or in control 
of the cell cycle[119]. In vascular smooth cells it was shown that after stimulation of platelet 
derived growth factor(PDGF), PDGF receptor binding caused peroxide formation which could be 
inhibited by the catalase. catalase expression inhibited PDGF signal trusduction by supressing 
protein tyrosine phosphorilation. Anti-oxidants, especially thiol-reducing agents such as N-
acetyl- cystein, could mimic the inhibitory effects of catalase and prevent redox activation of 
ligand-coupled protein kinase cascades. Exposure to high concentrations of H2O2 or strong pro-
oxidative changes in the intracellular thiol/disulfide redox state will generally lead to increased 
tyrosine phosphorilation in numerous proteins[120-123].  DNA demage is also seen in oxidative 
stress and it is one of the most published area. One of the most dangerous radical is hydroxyl 
radicals which arise either from the radiolysis of water by ionizing radiation, or from purely 
chemical source. Also metal-bound oxyl radicals are active intermediates in DNA demaging 
reactions and may be formed from syntetic compounds or from natural products such as 
bleomycin which is also used for cancer therapy[124,125]. Free radicals can cause DNA demage 
which can result in deletirous biological consequences such as the initiation and promotion of 
cancer. Thus characterization and quantitation of free radical induced DNA demage is really 
important for understanding of its biological consequences and cellular repair. Methodologies 
incorporating the technique of gas chromatography/mass spectrometry (GC/MS) have been 
developed in recent years for measurement of free radical induced DNA damage. The use of 
GC/MS with selected-ion monitoring (SIM) facilitates unequivocal identification and quantitation 
of a large number of products of all four DNA bases produced in DNA by reactions with 
hydroxyl radical, hydrated electron, and H atom. Hydroxyl radical induced DNA-protein cross-
links in mammalian chromatin, and products of the sugar moiety in DNA are also unequivocally 
identified. The sensitivity and selectivity of the GC/MS-SIM technique enables the measurement 
of DNA base products even in isolated mammalian chromatin without the necessity of first 
isolating DNA, and despite the presence of histones[126,127]. Redox status inside the cell is 
crucial for the correct enzymatic activity, this redox status can alter the enzymatic activity and its 
thought that alterations of the redox status could acct as a signalling mechanism. One of the most 
impotant redox-sensitive molecule is glutathione(GSH), GSH forms the GSH-GSSG couple. 
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Changes in GSH-GSSG status have been measured after cell stimulation. GSH content can be 
lowered by H2O2 , then redox status is altered and so propogation of a signal is induced by H2O2 
through this route. It is suggested that some of the enzymes such as ribonucleotide reductase and 
thioredoxin reductase and some of the transcription factors might be among the targets for altered 
redox status. GSH does not only act as an anti-oxidant, also it can modulate the activity of the 
various proteins via S-glutathionylation of cysteine sulfhydril groups. Also the thioredoxin 
system works with GSH system via reducing inter- and intrachain protein disulfide bonds as well 
as maintaining the activity of mportant antioxidant enzymes such as peroxiredoxins and 
methionine sulfoxide reductases[128-130]. NfkB/rel family also was shown to be activated not 
only by receptor-targeted ligands but also by direct application of oxidasing agents, particularly  
H2O2, or ionizing radiation[131,132].  
 
 
                                       2.3.4 ROS and MAPK Cascade 
 
 
           MAP kinase sinalling cascades are regulated by phosphoriltion and dephosphorilation on 
serine and or/threonine residues and they respond to stimulation of receptor tyrosine kinases, 
protein tyrosine kinases, receptors of cytokines and gowth factor, and heterotrimeric G protein-
coupled receptors[133-136]. There are currently four known MAPKs: the extracellular regulated 
kinase (ERK1/2), the c-Jun N-terminal kinase/stress activated protein kinase (JNK/SAPK), the 
p38, and the big mitogen-activated protein kinase 1 (BMK1). These pathways can be defined by 
a dual-phosphorylation motif that is required for activation: Thr– Glu– Tyr, Thr– Pro– Tyr, Thr– 
Gly–Tyr, and Thr– Glu– Tyr, for ERK1/2, JNK, p38, and BMK1,respectively[137,138]. In MAP 
kinase cascade, Each MAP kinase pathway has reltively distinct upstream mediators and specific, 
although multiple, substrates[139]. In many studies, it was shown that JNK and p38 are strongly 
activated by ROS or by a mild oxidative shift of the intracellular thiol/disulfide redox state[140-
146]. The extracellular signal-regulated kinase 1 (ERK-1) and ERK-2 were found to be activated 
in vascular smooth muscle cells by O2− but not by H2O2[147]. Angiotensin II induces the 
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production of O2− and H2O2 and it activates ERK-1, ERK-2, and p38 MAPK [148]. Platelet-
Derived Growth Factor Receptor (PDGF) was found to induce the activation of ERK-1 and ERK-
2. JNK and p38 MAPK were shown to be activated by H2O2 in perfused rat hearts. The redox 
sensitivity of JNK and p38 MAPK is depend on the oxidative activation of upstream tyrosine 
kinases called the Src family [148-151]. Numerous of cellular stimuli like inflammatory 
cytokines and environmental stresses can activate the c-Jun NH(2)-terminal kinase (JNK), ROS 
also cause activation of JNK [152,153]; however, the signalling cascade that leads to JNK 
activation remains to be elucidated. Because recently it was reported that expression of Cas, a 
putative Src substrate, stimulates JNK activation, it was thought that [152] the Src kinase family 
and Cas would be related to JNK activation by ROS. An essential role for both Src and Cas was 
demonstrated. First, the specific Src family tyrosine kinase inhibitor, PP2, inhibited JNK 
activation by H2O2 in a concentration-dependent manner but it had no effect on extracellular 
signal-regulated kinases 1 and 2 and p38 activation. Second, JNK activation in response to H2O2 
was completely inhibited in cells harvested from transgenic mice deficient in Src but not Fyn. 
Third, expression of a dominant negative mutant of Cas stops H2O2-mediated JNK activation but 
there is no effect on extracellular signal-regulated kinases 1 and 2 and p38 activation. The 
importance of Src was supported by the inhibition of both H2O2-mediated Cas tyrosine 
phosphorylation and Cas. Crk complex formation in Src−/− but not Fyn−/− cells [151,152]. The 
JNK/glutathione S-transferase Pi (GSTp) complex has also been characterized as a redox-
responsive signalling element. In normal growing cells of the mouse fibroblast cell line 3T3-4A, 
JNK is related with and catalytically inhibited by glutathione-S-transferase (GSTp). Complex 
formation between GSTp and JNK limits the degree of Jun phosphorylation under normal 
conditions. Exposure to low micromolar H2O2 concentrations causes the oligomerization of  
GSTp and the dissociation of the GSTp-JNK complex, supporting that JNK inhibition requires 
monomeric GSTp [153]. There is another kinase called apoptosis signalling kinase-1 (ASK1) 
plays a role in the activation of MKK3/6, MKK4/MKK7 and the MAP kinase species including 
p38, JNK. This leads to the phosphorilation of some transcription factors such as ATF-2, c-Jun 
and p53[154,155]. p38 MAP kinase pathway is a potential target of antioxidant antagonism in 
inflammatory diseses. p38 MAP kinase plays a role in expression of some of the cytokines such 
as IL1B, iNOS and COX-2[156-158]. 
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        2.3.5 ROS and Apoptosis  
 
 
      Apoptosis is a mechanism that can be described as a cellular suicidal process in 
response to various stimuli, ROS formation is one of the stimuli that can trigger apoptosis. 
Apoptosis also can be seen to regulate the body homeostasis in normal circumstances especially 
in developmental stage. An increase of ROS is generally seen in the apoptotic process triggered 
by such stimuli as APO-1/Fas/CD95 ligands. however some authors described that triggering of 
APO-1/Fas/CD95 ligands does not induce ROS production[159,160]. Also some authors 
observed membrane changes typical for apoptosis in the absence of ROS, these findings suggest 
that pro-oxidative conditions are not a general prerequisite for apoptotic cell death.[161].     
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        3  PURPOSE OF THE STUDY 
Pramanicin is a newly synthesized anti-fungal agent which has been shown to cause cell 
death and Calcium release in vascular endothelial cells by Kwan et al. (2003). Another study has 
recently shown its apoptotic effect in jurkat leukemia cell line in our laboratory by Kutuk et al. 
(2005) In the light of previous studies, Pramanicin analogues (PMC-A, C, E, F, G, I, H, J) have 
been screened by MTT assay and the most effective analog, PMC-A, has been studied 
mechanistically for a possible apoptotic effect in HCT 116 cells. In this study we tried to reveal;  
 
• The efficiency of pramanicin analogues and their time and dose kinetics in inducing 
apoptosis in HCT 116 cells. 
• The role of MAPK in this event by using of specific antibodies and inhibitors by 
immunoblotting and flowcytometric analyses with annexin-V staining. 
• The effect of caspase 3, 9 and general caspase inhibitors in apoptotic signaling. 
• To identify the role of ROS as second messenger in apoptotic signaling of PMC-A.   
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                4  MATERIALS AND METHODS 
  4.1 Materials 
 
4.1.1 Chemicals 
 
  
(in alphabetical order) 
 
Name of Chemical         Supplier Company        Catalog Number 
Acetic acid    Sigma, Germany          A9967 
Acrylamide/Bis-acrylamide  Sigma, Germany     A3699 
Ammonium persulfate   Sigma, Germany     A3678 
Antibiotic solution   Sigma, Germany     P3539 
Bradford solution   Biorad Inc.,USA    500-001 
Chloroform    Merck, Germany     102431 
CM-H2DCF-DA   Molecular Probes, USA    C-6827 
Coomassie Brilliant Blue  Merck, Germany     115444 
DMSO     Sigma, Germany     D2650 
EDTA     Riedel-de Haén, Germany    27248 
Ethanol     Riedel-de Haén, Germany    32221 
Foetal Bovine Serum   Sigma, Germany    F2442 
Glycerol    Riedel-de Haén, Germany    15523 
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Glycine     Amnesa, USA     0167 
HCl     Merck, Germany     100314 
Hepes     Sigma, Germany     H7006 
Hyperfilm ECL   Amersham Bio., UK                  RPN2114K 
Isopropanol    Riedel-de Haén, Germany    24137 
KCl     Fluka, Switzerland     60129 
KH2PO4    Riedel-de Haén, Germany   04243 
KOH     Riedel-de Haén, Germany    06005 
Liquid nitrogen   Karbogaz, Turkey  
2-Mercaptoethanol   Sigma, Germany     M370-1 
Methanol    Riedel-de Haén, Germany   24229 
MgCl2     Sigma, Germany     M9272 
Milk Diluent concentrate  KPL, USA      50-82-00 
NaCl     Riedel-de Haén, Germany   13423 
NaO2C2H3.3H2O   Riedel-de Haén, Germany    25022 
NaOH     Merck, Germany     106462 
NaPO4H2    Riedel-de Haén, Germany    04269 
NP-40     Sigma, Germany     I3021 
PD98059    Calbiochem, USA     513000 
Phenol     Applichem, Germany    A1153 
Phenol/chloroform   Applichem, Germany    A0889 
/isoamylalcohol 
Phosphate buffered saline  Sigma, Germany     P4417 
PMSF     Sigma, Germany     P7626 
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Propidium iodide   Sigma, Germany     P4170 
SB203580    Calbiochem, USA    559389 
SP600125    Calbiochem, USA    420123 
Sodium Dodecyl Sulphate  Sigma, Germany    L4390 
TEMED    Sigma, Germany    T7029 
Triton X-100    Applichem, Germany    A1388 
Tris     Fluka, Switzerland     93349 
Tween® 20    Merck, Germany     822184 
 
 
 
  
All chemicals used in this study were purchased from, Amresco, Applichem, 
Fluka(Switzerland), Calbiochem(USA),  Merck(Germany), Riedel de Haen(Germany), Sigma-
Aldrich(Germany) otherwise indicated. Pramanicin Analogues (PMC-A and others) were 
synthesized and sent from McMaster University, Canada. 
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4.1.2 Antibodies 
 
 
p44/42 MAP Kinase (137F5) Rabbit mAb # 4695 (Cell Signaling) 
 
SAPK/JNK (56G8) Rabbit mAb # 9258 (Cell Signaling) 
 
p38 MAP Kinase Antibody # 9212 (Cell Signaling) 
 
Phospho-p44/42 MAPK(Thr202/Tyr204)(D13.14.4E)Rabbit mAb#4370(Cell Signaling) 
 
Phospho-p38 MAPK (Thr180/Tyr182) Antibody # 9211 (Cell Signaling) 
 
Phospho-SAPK/JNK (Thr183/Tyr185) (81E11) Rabbit mAb # 4668 (Cell Signaling) 
 
Anti-rabbit IgG, HRP-linked Antibody # 7074 (Cell Signaling) 
 
 
4.1.3 Commercial Kits 
 
 
M30-Apoptosense™ ELISA Kit Peviva AB 
 
ECL Advance Chemiluminescence Amersham Biosciences , Detection Kit 
 
Cell Proliferation Kit I (MTT) Roche, Germany  
 
ECL Kit (Amersham Pharmacia) 
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4.1.4 Cells 
 
 
HCT 116 Wild Type Colon Cancer Cells 
 
 
4.1.5 Buffers and Solutions 
 
 
4.1.5.1 Cell Culture Media, Additions and Other Solutions for Cell Culture  
 
 
MACCOYs 5A medium with %5 L-glutamine 
 
Sterile FBS (Sigma) 
 
Penicillin-Streptomycin (Sigma) 
 
Sterile 1X PBS (Biological Industries) 
 
Sterile Tyripsin (Biological Industries) 
 
Sterile DMSO (Sigma) 
 
L-Glutamine (Sigma) 
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4.1.5.2 Western Blotting Buffers 
 
 
1X Tris-Glycine-SDS (sodium dodecyl sulfate) buffer was used for polyacrylamide gel 
electrophoresis. Gels were run at constant voltage, 100 mV, for about 1 hour. Transfer buffer 
(Tris base, Glycine and methanol) was used for blotting the proteins into PVDF membrane. The 
membranes were blocked with blocking solution, 5% milk powder in PBS-Tween 20 (0,25%) and 
washed with washing buffer, PBSTween 20 (0,25%). The antibodies were diluted in 5% milk 
diluent, 10% PBS-Tween 20 (0,25%) and 80% sterile distilled water. 
 
 
 
1X Running Buffer Tris-Glycin-SDS (10X Stock) 
 
1X Transfer Buffer Tris-Glycin (10X Stock) 
 
2X Laemli Buffer (Fermentas) 
 
10X PBS 
 
1X PBS-Tween (%0,2 Tween 20) 
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  4.1.6 Equipment 
 
 
Equipment that is used for general laboratory procedures are listed in Appendix A. 
 
 
4.2 Methods 
 
All methods used in this study are described below; 
 
 
4.2.1 Cell Culture 
 
 
HCT116 colon cancer cells were cultured in MACCOYs 5A medium with %5 L-glutamine 
supplemented with 10% heatinactivated FBS, 100 IU/ml penicillin and streptomycin. Cultures 
were maintained in 37°C in a humidified 5% CO2 atmosphere. Cells were seeded in 6-well 
culture plates (1 x 106 cells/well), 60 mm culture flasks (1x 107 cells/well) or 96-well plates (1 x 
104 cells/well) and treated as indicated in the experimental protocols. Ethanol was added to all 
control wells in each experiment. For cryopreservation, cells were trypsinized and resuspended in 
complete medium containing 10% heat-inactivated FBS and 10% DMSO (freezing medium). The 
cell suspension in freezing medium transferred into cryovials, frozen at -70 º C for 24 hours, and 
then stored in liquid nitrogen to remain until thawing. 
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4.2.2 Cryopreservation 
 
 
For cryopreservation, cells were trypsinized and resuspended in complete medium 
containing 10% heat-inactivated FBS and 10% DMSO (freezing medium). The cell suspension in 
freezing medium transferred into cryovials, frozen at -70 º C for 24 hours, and then stored in 
liquid nitrogen to remain until thawing. 
 
 
4.2.3 Pramanicin-A(PMC-A) and PMC-F Treatment 
 
 
HCT116-wt colon cancer cells were seeded 200.000cells/well to 6-well plates, then cells 
were treated with PMC-A(25uM from 20mM stock) and PMC-F(75uM from 20mM stock) at 
%80 confluency for 30min,1h,2h,4h,8h. PMC-A and PMC-F were delivered in lyophilized 
powder and they were dissolved in ethanol for stock solutions, 2,5ul of each pramanicin analogue 
were applied to wells, 2,5ul ethanol was added to controls. At each time points mediums were 
discarded and proteins were isolated as described below. 
 
 
4.2.4 Total protein isolation 
 
 
Treated and control HCT116 wild-type(wt) cells were harvested, washed with ice-cold 
phosphate buffered saline and lysed on ice in a solution containing 20 mM Tris-HCl (pH 7.5), 
150 mM NaCl, Nonidet P-40 0.5%, (v/v), 1 mM EDTA, 0.5 mM PMSF, 1mM DTT, protease 
inhibitor cocktail (Complete from Roche, Mannheim, Germany) and phosphatase inhibitors 
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(Phosphatase inhibitor cocktail 1 and 2, Sigma, Darmstadt,Germany). After cell lysis, cell debris 
was removed by centrifugation 15 min at 13000g and protein concentrations were determined 
with Bradford protein assay.  
 
 
4.2.5 Protein Content Assay  
 
 
Protein concentrations were determined with DC protein assay (Biorad). 3 - 5 dilutions of a 
protein standards containing from 0.2 mg/ml to about 1.5 mg/ml protein were prepared. (Note: A 
standard curve should be prepared each time the assay is performed). 5 µl of standards and 
samples were pipeted into a clean, dry microtiter plate.Then 25 µl of reagent A' or reagent A was 
added into each well. After adding reagent A, 200 µl reagent B was added into each well and 
mixed by pipeting up and down. After 15 minutes in room temperature, absorbances was read at 
695 nm.  
 
 
4.2.6 SDS-PAGE 
 
 
Biorad mini potein gel systems were used for protein electrophoresis. %12 SDS-PAGE was 
prepared by mixing the proper amount of distilled water, pH 8.8 1.5M Tris-HCl-SDS, %30/%0.8 
acrylamide/bisacrylaide, %10 APS and TEMED for seperating gel. Then gels were overlaid with 
isopropanol to initiate polymerization. Once gels were formed then isopropanol was removed and 
gels were washed with distilled water. Then stacking gels were prepared by mixing the proper 
amount of distilled water, pH 6.8 0.5M Tris-HCl-SDS, %30/%0.8 acrylamide/bisacrylaide, %10 
APS and TEMED and poured onto the seperating gels. Well combs were placed for the formation 
of wells.  Polymerized gels were put into tanks and tanks were fulled with 1X running buffer. 
Equal amount of protein samples were prepared and mixed with 2X loading dye (125mM Tris 
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pH6.8, %4 SDS, %10 glycero, %0.5 bromophenol blue and  %1.8-2 mercaptoethanol). Samples 
were denaturated at 95°C for 3 minutes, then centrifuged shortly at high speed for 10 seconds. 
After that, each of the samples was loaded to the wells along with a 4ul protein marker. Gels 
were run at 100V for 1-1,5 hours. After running step, proteins were transfered to PVDF 
membranes at 60V for 1 hour, and immunoblottings were done described as below. 
 
 
4.2.7 Immunoblots 
 
 
Proteins (50 µg) were separated on a 10-15% SDS-PAGE and blotted onto PVDF 
membranes. The membranes were then blocked with 5% dried milk in PBS-Tween20 and 
incubated with appropriate primary(1:2000) and horseradish peroxidase (HRP)-conjugated 
secondary antibodies(1:10000) (Amersham Pharmacia Biotech, Freiburg, Germany) in antibody 
buffer containing 5% (v/v) Milk Diluent/Blocking concentrate. After required washes with PBS-
Tween 20, proteins were finally analyzed using an enhanced chemiluminescence detection 
system (ECL-advanced, Amersham Pharmacia Biotech, Freiburg, Germany) and exposed to 
Hyperfilm-ECL (Amersham Pharmacia Biotech, Freiburg, Germany).  
 
 
4.2.8 Apoptosis and cell death 
 
 
4.2.8.1 MTT assay 
 
 
In order to determine cell viability, Cell Proliferation Kit I (MTT Roche, Mannheim, 
Germany) has been used. MTT Assay is designed for the spectrophotometric quantification of 
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cell growth and viability without the use of radioactive isotopes. The assay is based on the 
cleavage of yellow tetrazolium salt, MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium 
bromid) to purple formazan crystals by viable cells. The formazan crystals formed are solublized 
and the resulting solution, which is colored, can be quantified by spectrophotometer. According 
to the protocol, HCT116-wt cells(1X106) were grown on 96-well plates, starved with MACCoy’s 
Modified medium supplemented with 0.2% Fetal calf serum overnight. After treatment, the 
medium was changed and 10 mL of the MTT labeling reagent was added to each well and 
incubated under humidified atmosphere containing % 5 CO2 at 37°C for 4 hours. Then 100 mL 
of the solubilization solution was added into each well and incubated under humidified 
atmosphere containing % 5 CO2 at 37°C overnight. Spectrophotometrical absorbance of the 
samples was measured  by Model 680 Microplate Reader (Bio-Rad, CA, USA) at 550 nm. 
Percent viability was calculated as (OD of drug-treated sample/control OD) X 100. 
 
 
4.2.8.2 M30 Apoptosense®Elisa Assay 
 
  
First day HCT116-wt colon cancer cells were seeded the density of 10,000 cells per well in 
a 96-well plate. Second day cells were washed once with PBS and add fresh medium (200 
µl/well).Then cells were exposed to PMC-A(25uM from 20mM stock) and PMC-F(75uM from 
20mM stock). After 24h treatment, 10 µl 10% NP-40 added  per well and allowed lysis for 5 
minutes at room temperature. 2x25 µl of the medium/lysate were transfered to wells of an M30-
Apoptosense plate. And absorbance was read at 450nm with microplate elisa reader.   
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4.2.9 ROS Production 
 
 
4.2.9.1 Flourometric Analysis for ROS Production 
 
 
In order to quantify the ROS production in HCT116-wt colon cancer cell line. Cells were 
grown in 12-well plate, after treatment of PMC-A(25uM from 20mM Stock) cells were washed 
with PBS twice, and then incubated with DC-FHDA (1 mM) for 30 minutes. Cells were washed 
with PBS to remove the excess dye and read on Microplate Reader (Spectra Max Gemini XS) 
with an excitation wavelength of 485 nm and an emission wavelength of 530 nm. The increase in 
absorbance indicates ROS production. 
 
 
4.2.9.2 Flow-cytometric Analysis of ROS Production 
 
 
In order to show the ROS production in HCT116-wt colon cancer cells with flow-cytomety. 
Cells were grown in 12-well plates, after treatment of PMC-A (25uM from 20mM Stock) for 24 
hours, cells were washed with PBS twice, and then incubated with DC-FHDA (1 mM) for 30 
minutes. Cells were washed with PBS to remove the excess dye, again 500ul PBS were added to 
wells, then 200ul PBS with cells were taken to 96-well plate by pipet up and down, and read on 
BD-FACS CANTO with an excitation wavelength of 485 nm and an emission wavelength of 530 
nm. 
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4.2.9. Statistical Analysis 
 
 
The results are expressed as mean ± SEM and the mean values were compared using 
Students t-tail test or one-way ANOVA analysis. Values of P<0.05 and P<0.01 were considered 
statistically significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 39 
         5. RESULTS  
5.1 Determination of Pramanicin Analogs-Induced Cytotoxicity in HCT116-wt Colon 
Carcinoma Cells   
In order to investigate the potential effect of pramanicin analogs (A,C,E,F,G,H,I,J) on     
HTC-wt cells, cell viability was checked by using MTT assay. As shown in Figure 5.1, treatment 
of HCT-wt cells with pramanicin’s analogs, some of the analogs significantly affects viability of 
the HCT116 cells. Treatment of HCT116-wt cells with 100uM each of the pramanicin analogs for 
24 hour, some of the analogs (esp. PMC-A and PMC-F) showed significant potential in 
decreasing cell viability compared with untreated control and ethanol control. Because of the 
significant potential of PMC-A and PMC-F, they were selected for further investigations. Ethanol 
control was used because of all PMC analogues were dissolved in pure ethanol.     
 
 
 
 
 
Figure 5.1 Pramanicin’s analogs induce cell death. HCT-wt cells were treated with 100uM each of the 
pramanicin’s analogs for 24 h and after incubation, cell viability was assessed using MTT assay. Results are 
expressed as means ±SEM from the experiment performed in triplicate.  
 
 40 
  5.2 Determination of the PMC-A and PMC-F Concentration  
 
For determining the minimum potential dose of PMC-A and PMC-F, HCT-wt cells were treated with 
differing dose (from 25uM to 75uM, 100uM were not screened since the previous experiments 
showed the effect of 100uM concentrations of PMC-A, F) of PMC-A and PMC-F for 24 h. After 
incubation, cell viability was checked by using MTT assay. As demonstrated in Figure 5.2 25uM for 
PMC-A and 75uM for PMC-F were selected for further experiments as minimum effective dose.   
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Figure 5.2 Different dose of Pramanicin-A and Pramanicin-F induce cell death in HCT-wt cells. HCT cell lines 
were treated with differing dose of the pramanicin-A and pramanicin-F analogs for 24 h and after incubation, cell 
viability was assessed using MTT assay. Results are expressed as means ±SEM from the experiment performed in 
triplicate. 
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5.3 Determination of PMC-A Cytotoxic Potential on Different HCT Cell Lines   
 
In order to show the effect of the most potent PMC analog PMC-A on different HCT cell 
lines (wt, Bax-/-, Puma-/-), MTT assay was used at the concentration of 100uM PMC-A. 
Treatment of different HCT cell lines with 100uM of the pramanicin-A analog for 24 hour. As 
shown in Figure 5.3. There was no significant change in cell viability among the different 
HCT cell lines. This result suggests that PMC-A induced cytotoxicity is independent from 
BAX and PUMA mediated pathways.Thus HCT-wt was selected for the further investigations 
 
    
 
 
 
 
 
Figure 5.3 Pramanicin-A induce cell death in different HCT cell lines (wt, puma-/-, bax-/-). HCT cell lines 
were treated with 100uM of the pramanicin-A analog for 24 h and after incubation, cell viability was assessed 
using MTT assay. Results are expressed as means ±SEM from the experiment performed in triplicate. 
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5.4 Comparison of PMC-F and the First Synthesized Pramanicin Analog PMC 
Potentials   
PMC was the first synthesized drug among the other analogs and was demonstrated its 
potential of apoptotic function on Jurcat cells (Kutuk et. al, Apoptosis 2005 ; 10:597-609) we 
compared the PMC-F and PMC potentials on HCT-wt cells in a dose- dependent manner. As 
shown in Figure 5.4. HCT-wt cells were treated with differing dose of PMC and PMC-F for 
24 h. After incubation, cell viability was checked by using MTT assay. As shown in Figure 
5.4, PMC is not potent as PMC-F, Kutuk et al. (2005) showed PMC very effective on jurkat 
cells, but in our case probably because of the cell type difference PMC is not as effective as 
PMC-F. Also we could conclude that PMC-F is only as potent as PMC-A at the concentration 
of 200-250uM compared to previous MTT assay results in Figure 5.4, Figure 5.1. 
 
  
 
 
 
 
 Figure 5.4 Different dose of Pramanicin (PMC) and Pramanicin-F(PMC-F) induce cell death in 
HCT-wt cells. HCT cells were treated with differing dose of the pramanicin and pramanicin-F for 24 h and after 
incubation, cell viability was assessed using MTT assay. Results are expressed as means ±SEM from the 
experiment performed in triplicate. 
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5.5 PMC-A and PMC-F Induce Apoptosis in HCT-wt Cells 
 
In order to investigate if PMC-A and PMC-F induce apoptosis, Flow Cytometric 
analysis Figure 5.5A and M30-Apoptosense® ELISA Figure 5.5B were performed. HCT-wt 
cells were treated with 25uM PMC-A and 75uM PMC-F for 24 h. As demonstrated in Figure 
5.5A, Figure 5.5B. Compared to PMC-A, PMC-F was found less potent for its apoptotic 
efficiency, thus PMC-A were selected for further experiments.  
 
 
 
 
 
Figure 5.5A PMC-A and PMC-F induce apoptosis, HCT-wt cells were treated with 25uM PMC-A and 
75uM PMC-F for 24 h, after incubation flowcytometry was performed with FITC(Fluorescein isothiocyanate). 
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Figure 5.5B PMC-A and PMC-F induce apoptosis, HCT-wt cells were treated with 25uM PMC-A and 
75uM PMC-F for 24 h, after incubation M30-Apoptosense® ELISA was performed. 
 
                  5.6 PMC-A Activates P38, JNK, ERK-1, 2 
 
In order to understand the expression profiles of MAPKs to PMC-A treatment in HCT116-wt 
cells, immunoblot analysis was performed. HCT116-wt cells were treated with 25uM PMC-A 
in a time dependent-manner, after incubation, proteins were isolated at 30min-8h time period. 
From each sample tube 50ug protein were loaded to the SDS-PAGE, after blotting, 
membranes were probed suitable antibodies at 1/2000 for primary and 1/10000 for secondary 
antibody dilution from the stocks. As shown in Figure 5.6A, Pramanicin-A induces P38 
activation at early time point at 1h without any changes of P38 protein level. Maximum level 
of phosphorilation of P38 was observed at 1h and P38 returns its basal level at 8h compared to 
nontreated control. As shown in Figure 5.6B, Pramanicin-A also induces ERK-1, 2 
phosphorilation at 30 min and maximum level of phosphorilation was observed at 4h, then 
there is a slight decrease of its activation at 8h. Finally as demonstrated in figure 5.6C there is 
a slight activation of JNK at 30min and maximum level of JNK activation is seen at 8h 
compared to control.            
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  Figure 5.6A PMC-A induces P38 activation, HCT116-wt cells were grown on 60mm cell culture 
flasks and treated with 25uM PMC-A for 0-8 h, activities of P38 was shown in immunoblot analysis. Specific 
antibodies were used against total P38, phospho-P38, B-actin was used as a loading control for immunoblots. 
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  Figure 5.6B PMC-A induces ERK-1,2 activation, HCT116-wt cells were grown on 60mm cell culture 
flasks and treated with 25uM PMC-A for 0-8 h, activities of ERK-1,2 were shown in immunoblot analysis. 
Specific antibodies were used against total ERK-1,2, phospho-ERK-1,2, B-actin was used as a loading control for 
immunoblots. 
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          Figure 5.6C PMC-A induces JNK activation, HCT116-wt cells were grown on 60mm cell culture flasks 
and treated with 25uM PMC-A for 0-8 h, activities of JNK were shown in immunoblot analysis. Specific 
antibodies were used against, phospho-JNK, B-actin was used as a loading control for immunoblot. 
 
 
5.7 Effect of JNK, p38, ERK1/2 and Caspase Inhibition on PMC-A Induced Apoptosis 
 
In order to investigate the role of MAPKs, JNK, p38, ERK1/2 and Caspases, Caspase-3, 
Caspase-9 in apoptotic response of HCT116-wt cells to PMC-A, we applied specific 
inhibitors of MAPKs and Caspases. As shown in Figure 5.7, Caspase inhibitors effectively 
prevent PMC-A induced apoptosis, in contrast MAPK inhibitors did not show any preventive 
effect, but JNK and p38 inhibition did potentiate the apoptotic response of HCT116-wt cells 
to PMC-A treatment. For the experiment HCT-wt cells were treated with 25uM PMC-A for 
24 h, 10uM of each specific MAPKs inhibitors were applied 1 hour before the PMC-A 
treatment (JNK inhibitor, p38 inhibitor, ERK1/2 inhibitor; SP600125, SB203580, PD98059). 
Also 20uM of  each specific caspase inhibitors (Caspase3,9 and pancaspase inhibitor) were 
applied 30 minutes before the treatment. After 24 hours treatment, samples were stained with 
Annexin-V dye for 15 minutes and they were read with BD-Facs Canto flow-cytometry 
machine. These results indicate that, PMC-A induced apoptosis in HCT116-wt cells depends 
on caspase cascades, in contrary inhibition of JNK and p38 did not show any preventive effect 
on apoptosis. Interestingly, JNK and p38 inhibition potentiated the apoptotic response of 
HCT116-wt cells to PMC-A treatment. Even if ERK1/2 signaling cascades play a survival 
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role in many cells lines, in our case ERK1/2 inhibition also did not effect the survival 
response of HCT116 cells.  
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Figure 5.7 Effect of specific Caspase and MAPK inhibitors on apoptosis induced by PMC-A 
HCT116-wt cells were treated with 25uM PMC-A for 24h with or without 10uM specific MAPKs 
inhibitors(JNK inhibitor, p38 inhibitor, ERK1/2 inhibitor; SP600125, SB203580, PD98059 1h prior to PMC-A 
treatment) and specific caspase inhibitors(Caspase-3, caspase-9 and general caspase inhibitor 30 minutes prior 
toPMC-A treatment), after 24 hours incubation, cells were stained with annexin-v dye for 15 min at room 
temperature and immediately flowcytometric analysis was performed. 
 
5.8 PMC-A Mediates ROS Production in HCT116-wt Cells 
To test the possible role of PMC-A in ROS production, H2DCF-DA was used with 
flowcytometric method. As shown in Figure 5.8A(early points) and Figure 5.8B(late point), 
HCT116-wt cells were treated with 25uM PMC-A for early points for 2h, 4h and late point for 
24h with or without NAC(n-acetyl cysteine) as an antioxidant, after incubation, cells were 
stained with H2DCF-DA for 30 min at 37º and immediately flowcytometric analysis was 
performed with 200.000cells/tube. There is a significant increase of ROS production upon 
25uM PMC-A treatment for 24h Figure 5.8B, whereas there is a slight increase after 2h of the 
treatment observed, a small decrease was observed at 4h Figure 5.8A. At 24h some of the 
sample’s mediums were changed before staining with H2DCF-DA for 30 min at 37 centigrade 
degree. (24pmcM and 24pmcnacM samples shown in figure 5.8B), there is a significant 
recover of the cells from ROS production was observed after PMC-A was taken away. 
Samples with NAC pretreated prior to PMC-A treatment did not show any change of the ROS 
production, NAC is generally involved in H2O2 mediated oxidative stress, this result might 
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indicate that in our case the oxidative stress is independent from H2O2 mediated oxidative 
process, or apoptotic formation of the cells might have generated the ROS.    
      
 
Figure 5.8A PMC-A induces ROS production, HCT116-wt cells were treated with 25uM PMC-A for early 
points as 2h, 4h with or without 50mM NAC(n-acetyl cysteine) as an antioxidant(2h prior to PMC-A treatment), 
after incubation, cells were stained with H2DCF-DA for 30 min at 37º and immediately flowcytometric analysis 
was performed. 
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 Figure 5.8B %Cells with ROS production induced by PMC-A. HCT116-wt cells were treated with 
25uM PMC-A for late point as 24h with or without 50mM NAC(n-acetyl cysteine) as an antioxidant(2h prior to 
PMC-A treatment), after incubation, cells were stained with H2DCF-DA for 30 min at 37º and immediately 
flowcytometric analysis was performed. * Medium changed before staining for 30 min. 
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5.9 Flourometric Analysis of ROS Production in HCT116-wt Cells Treated with PMC-A 
in a Time-Dependent Manner 
 
To investigate the ROS production in a time-dependent manner,and to understand when the 
ROS production starts after treatment of PMC-A, H2DCF-DA were used with flourometric 
method. HCT116-wt cells were treated with 25uM PMC-A for early points 0-8h with or 
without 50mM NAC(n-acetyl cysteine) as an antioxidant(adding 2h before the treatment of 
PMC-A), after incubation, cells were stained with H2DCF-DA for 30 min at 37º and 
immediately flourometric analysis was performed at 532 wave length. As demonstrated in 
Figure 5.9, ROS production slightly increases at early time points at 1h and a slight decrase 
was observed at 4h, this might have an experimental error or a defence response. As shown in 
figure 5.8B after 24h treatment ROS production is significantly increases. These results 
indicate that early ROS production might mediate MAPKs early signaling pathways in other 
word initiates MAPKs signaling but further experiments with antioxidants must be done for 
verifying. On the other hand late excessive ROS accumulation might be a cause for apoptosis 
as well as other activated pathways upon the PMC-A treatment including MAPK’s signaling 
pathways in HCT116-wt cells.  
 
Figure 5.9 Flourometric analysis of ROS production induced by PMC-A, HCT116-wt cells were treated 
with 25uM PMC-A for early points 0-8h with or without 50mM NAC(n-acetyl cysteine) as an 
antioxidant(adding 2h before the treatment of PMC-A), after incubation, cells were stained with H2DCF-DA for 
30 min at 37º and immediately flourometric analysis was performed at 532 wave length. 
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         6. DISCUSSIONS AND CONCLUSIONS 
  6.1 PMC-A Induces Apoptosis in HCT116-wt Colon Cancer Cells 
 
 
Cancer is now the most important health issue around the world. Milions are dying 
from various kinds of cancers every year. Among all types of cancer, Colon cancer is the 3. 
most seen and dangerous cancer type in both male and female. Finding novel strategies in 
cancer prevention, diagnosis and treatment has been the most important step for humankind in 
medical field, many researchers are now trying to reveal the mechanistic pathways of the 
cancer formation and its proliferation, methastasis mechanisms to find the new treatments for 
people suffering from cancer. Every day many agents are being discovered and their apoptotic 
functions are being shown in various kind of cancer cells. Pramanicin has been recently found 
as a potential apoptotic agent which can be an anti-cancer drug among many others. 
Pramanicin (PMC) is an anti-fungal agent which was isolated from a sterile fungal 
fermantation of Stagonospora. It has 10 analogues as shown in Figure 1.1 It has been recently 
shown that PMC increases cytosolic calcium concentration and induces cell death in 
endothelial cells[2]. Also Kutuk et al. have been recently shown the pramanicin’s apoptotic 
effects on jurkat cells[16]. Thus the recent studies have been shown us, PMC and its 
analogues could be the potential chemotherapeutic agents which are important to be clarified 
their apoptotic machinery. Determination of cytotoxic effects of pramanicin analogues by 
MTT assays revealed that, PMC-A and PMC-F are the most effective analogues at 100uM 
concentration among others in HCT116-wt colon cancer cells Figure 4.1. Then apoptotic 
effects of  PMC-A and PMC-F was determined with flowcytometric analyses and M30 
apoptosense elisa assay, Our results demonstrated that PMC-A and PMC-F treatments induce 
apoptosis in  HCT116-wt colon cancer cells in a dose and time dependent manner. PMC-A’s 
apoptotic effect was found efficient at the concentration of 25uM, whereas PMC-F was 
efficient at the concentration of 75uM, Also in our results, we have found PMC-A more 
potential then PMC-F Figure 4.5A, Figure 4.5B. For further studies, PMC-A has been 
selected. Importantly, Screening of the pramanicin analogues for their cytotoxic potentials in 
HCT116-wt colon cancer cells showed us, their different molecular formations effect their 
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fuctionality, when PMC’s molecular structure is changed, its functions can be totally impaired 
or potentiated. According to Kutuk et al., PMC is at 100uM concentration is a very potential 
apoptotic agent in jurkat cells, in our study, it was seen that PMC is at 100uM concentration 
not as potent as PMC-A and PMC-F in HCT116-wt colon cancer cells compared to jurkat 
cells. Thus, it is so clear that different cell lines effected apoptotic potentials of PMC and its 
analogues. Also shown in Figure 5.3 the most effective analogue,PMC-A, was applied to 
different HCT knock-out cell lines (bax-/- and puma-/-), our data indicate that, neither bax nor 
puma mediated pathways are involved in apoptotic response of HCT116 cells, thus HCT116 
wild type cells were selected for further experiments. In conclusion, Our results demonstrated 
that PMC-A and PMC-F are very potential apoptotic agents for HCT116-wt colon cancer 
cells, and their apoptotic potentials should be clarified based on their different molecular 
structures in different cancer cell lines. Also animal experiments are needed to see their 
effects in vivo models.   
 
 
       6.2 PMC-A Activates JNK, ERK1/2 and P38 
 
 
In mammals, three different groups of mitogen-activated protein kinases(MAPKs) are 
defined, many types of stress like UV radiation, growth factor withdrawal and pro-
inflammatory cytokines can activate c-Jun N-terminal kinase and p38 MAPKs [5,6]. After 
phosphorilation by their upstream kinases on dual tyrosine/threonine, they are activated. P38 
and JNK phosphorilate many transcription factors like c-Jun, p53 and ATF-2, and regulate 
essential functions in cells including proliferation, cell cycle progression, gene expression and 
apoptosis[7]. JNK and p38 kinases have been described to function pro-apoptotic or anti-
apoptotic in many different studies[8,9,10,11]. Even if apoptosis is not seen in response to 
many stimuli, JNK and p38 MAP kinases activations were shown[12,13]. The other MAP 
kinase called extracellular signal regulated kinases (ERK1/2, p42/p44 kinases) can be 
activated by growth factors and mitogenic stimuli[14,15]. There have been many studies on 
MAP kinases. Their function is determined by cell type, stimuli origin, duration, initial 
magnitude, further amplification of the activated signal trunsduction pathway, co-activation of 
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other signaling pathways. Also they have reported that they can be also activated without 
apoptosis in response to many stimuli. Thus the activation patterns of MAP kinases must be 
carefuly evaluated in their pro-/anti-apoptotic properties in the light of the above 
parameters[12,13,16]. As described above, MAPKs pathways play an important role for cells 
to go apoptosis or to survive in response to many stimuli. After showing the apoptotic 
function of PMC-A, we investigated activation of MAPKs with their specific anti-bodies by 
immunoblotting and their roles in PMC-A induced apoptosis with their specific inhibitors. 
Our data demonstrated that, all three MAPKs including JNK, p38 and ERK1/2 are activated 
in different time kinetics and amplitudes. PMC-A at 25uM concentration led to an early 
activation of p38 at 1h, also increased p-JNK level was seen at early time point at 30min but it 
reached maximum level at 8h compared to non-treated control. ERK1/2 activation was seen at 
very early time point at 30min, the maximum level of ERK1/2 was seen at 4h in response to 
PMC-A treatment in HCT116-wt colon cancer cells. Involvement of MAPKs in PMC-A 
induced apoptosis was evaluated by using their specific inhibitors. Caspase inhibitors 
successfully inhibited the PMC-A induced apoptotic response compared to the nontreated 
control and revealed the functional involvement of the caspase pathway, also caspase-3 and 
caspase-9 activations were shown by Gizem Karslı with western blotting, thus this finding has 
been verified by her results as PMC-A induced apoptosis through caspase dependent pathway. 
However Pretreatment of caspase inhibitors (specific casp-3, casp-9 and general caspase 
inhibitor) effectively prevented the apoptosis induced by 25uM PMC-A. But pretreatment of 
specific JNK (SP6001259 and p38 (SB203580) inhibitors did not have any preventive effect 
on apoptosis induced by 25uM PMC-A, but they potentiated the apoptotic response of 
HCT116-wt cells. Also involvement of ERK1/2 was investigated by its specific 
inhibitor(PD98059) but results showed that, ERK1/2 inhibition did not effect apoptosis in 
response to PMC-A treatment, also did not potentiate apoptosis in HCT116-wt cells. All these 
data (inc. gizems data) indicate the functional role of caspases on apotosis induced by PMC-
A. On the other hand, inhibition of JNK and p38 did not effect apoptosis, but potentiate the 
apoptotic response of HCT116-wt cells. As discussed in Lim SJ et. al. 2006 and Sung-Ho 
Kook et. al. 2008, inhibition of JNK and p38 in some cases sensitize tumor cells to apoptosis 
induced by various anti-cancer molecules. In the light of the previous studies, our data show 
that JNK and p38 might play a pivotal role of surviving response of HCT116-wt cells in 
response to PMC-A insult. Even if ERK1/2 play a survival role in many stimuli in many cell 
lines, our datas showed that in HCT116-wt cells, ERK1/2 was not involved in apoptosis 
induced by PMC-A. MAP kinases are a protein kinase family which can phosphorilate many 
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transcription factors including c-jun, atf-2 and p53, and regulate various kinds of gene 
expressions which can play a role in cell survival and death. In our study activation of 
MAPKs including JNK, p38, and ERK1/2 were shown, we further will investigate the 
downstream elements of MAPKs such as atf-2, p53 and especially c-jun which forms AP-1 
with c-fos. Also specific inhibitors of MAPKs will be used and downstream elements will be 
checked for revealing the mechanistic pathway. 
 In conclusion, we report on the activation of JNK, p38 and ERK1/2 in response to 
PMC-A treatment, inhibitory experiments showed that, JNK and p38 were not major elements 
in apoptotic response of HCT116-wt cells, otherwise they dont play a pro-apoptotic role, but 
their inhibitions potentiate the apoptotic response of HCT116-wt cells. In contrast, inhibitions 
of caspases prevented the apoptotic response, these data suggest that, the apoptotic response 
depend on the caspase cascades, but not MAPKs cascades. For further evaluations of MAPKs 
functions in apoptotic response of HCT116-wt cells to PMC-A, downstream and upstream 
elements such as p53, atf-2, chop, elk-1 and c-jun should be investigated in further studies. 
Also focusing on different cancer cell lines and/or animal models will further extend our 
knowledge of mechanisms involved in apoptotic response to pramanicin analogues, and let us 
evaluate the anti-cancer potential of these molecules.   
 
 
         6.3 PMC-A Induces ROS Production      
 
 
Molecular signaling cascades in the cells are activated by various stimuli, one of the 
major activator is oxidative stress. Increase in the reduction potential or a large decrease in 
reducing capacity of the cellular redox couples can be described as oxidative stress. Reactive 
oxygen species (ROS) which include free radicals and peroxides can be produced by many 
mechanism in cells and can be so dangeous. Oxidoreduction reactions with transition metals 
can easily convert less reactive ROS species to more reactive and dangerous species. These 
highly active ROS species can cause extensive cellular demage. In animals, ROS may cause 
cell proliferation, cell death, and expressions of some ROS related genes, activation of 
cellular signaling cascades such as those involving mitogen activated protein kinases 
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(MAPK). Most of the ROS species can be produced by aerobic metabolism at a low level 
from mitochondria and can be easily repaired by some of the spesific mechanism in the cells. 
In cells, there are enzymes and antioxidants which preserve the cellular redox environment 
and maintain the reduced state through a constant input of metabolic energy. Oxidative stress 
is also one of the major causes of apoptosis which is involved many diseases like diabetes and 
neurodegenerative diseases. In our study, we showed production of reactive oxygen species at 
early (1h, 2h) and late (24h) time points by flowcytometric and flourometric H2DCF-DA 
staining with maximum ROS production at 24h. Intrestingly a fluctuation at 4h was seen also 
in flourometric and flowcytometric anaylsis. At the same time point ERK1/2 activation was 
seen at maximum level, these results can be speculated that there might be a relationship 
between ERK1/2 activation and decreased level of ROS production at 4h in response to PMC-
A treatment or independently cells might try to recover from ROS by activating their 
antioxidant mechanisms. ROS production is one of the activator of MAPK signaling pathway 
as well as other signaling cascades and also ROS can play as a secondary messenger role in 
various kinds of stimuli. Our results indicated activation of MAP Kinases including all three 
MAPKs, JNK, p38, ERK1/2. Their activations might related to early ROS formation or the 
early activations of MAPK pathways can mediate ROS production, but verifications with anti-
oxidants or overexpression studies with MAP kinases are needed to reveal the relationship 
between ROS production and MAPK activations. It is reported that excessive ROS production 
can cause apoptosis in many studies, in our case ROS production might be at least one of the 
reasons that mediate PMC-A induced apoptosis in HCT116-wt cells. After showing ROS 
production, we then tryed to reverse oxidative stress with a general antioxidant, N-acetyl-
cystein (NAC). However we could not see any effect on ROS production in response to NAC 
pre-treatment. Even if NAC is a general antioxidant which can particularly prevent H2O2 
mediated oxidative stress, we further will try other anti-oxidants which have different anti-
oxidant mechanism such as Vitamin E, catalase in our study, then we will further investigate 
the activation paterns of MAPKs and see whether MAPKs activations depend on ROS 
production or not. And also using anti-oxidants could let us see if the PMC-A induced 
apoptotic response of HCT116-wt cells is related to ROS production in our further studies. 
Finally, using different anti-oxidants in our case will also let us to find the mechanism of the 
ROS formation in response to PMC-A treatment.       
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 7 FUTURE WORK 
Đn the light of the results reported herei we would like to suggest the following studies; 
 
• Identifying the relationship between MAPK pathway activation and ROS 
generation by using specific antioxidants for reversing the oxidative stress and 
screening paterns of the phosphorilated MAPK family members with their 
specific anti-bodies by immunoblotting in apoptotic response of HCT116 cells 
induced by PMC-A. Also identifying the role of ROS on the apoptotic response 
through the use of specific anti-oxidants such as vitamin E and catalase.   
• Identifying the role of ROS production on the activation of caspase-3 and 
caspase-9 via specific caspase enzymatic assays and immunoblotting with or 
without specific anti-oxidant treatment in HCT116 cells treated with PMC-A.  
• Investigating the down-stream and up-stream elements of activated MAPK 
pathway such ATF-2, p53, CHOP, Elk-1 etc. in response to PMC-A treatment in 
HCT116 cells.    
• The role of JNK and p38 on apoptotic response of HCT116 cells induced by 
PMC-A through overexpressions of these proteins. 
• Possible cross-talk between MAPK pathway and BCL-2 family members in 
apoptotic response of HCT116 cells induced by PMC-A by western blotting and 
co-IP. 
• Effects of PMC analogues on different cancer cell lines.       
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     APPENDIXES 
     APPENDIX A 
 
 
Autoclave:   
Hirayama, Hiclave HV-110, JAPAN 
Certoclav, Table Top Autoclave CV-EL-12L, AUSTRIA 
Balance:   
Sartorius, BP211D, GERMANY 
Sartorius, BP221S, GERMANY 
Sartorius, BP610, GERMANY 
Schimadzu, Libror EB-3200 HU, JAPAN 
Blot Module X Cell II ™ Blot Module, Novex, USA 
 
Centrifuge:   
Eppendorf, 5415C, GERMANY 
Eppendorf, 5415D, GERMANY 
Eppendorf, 5415R, GERMANY 
Kendro Lab. Prod., Heraeus Multifuge 3L, GERMANY 
Hitachi, Sorvall RC5C Plus, USA 
Hitachi, Sorvall Discovery 100 SE, USA 
Deepfreeze:   
-70o C, Kendro Lab. Prod., Heraeus Hfu486 Basic, GERMANY 
-20o C, Bosch, TÜRKĐYE 
Distilled Water:   
Millipore, Elix-S, FRANCE 
Millipore, MilliQ Academic, FRANCE 
Electrophoresis:  
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Biogen Inc., USA 
Biorad Inc., USA 
X Cell SureLock ™ Electrophoresis Cell, Novex USA 
Gel Documentation:  
UVITEC, UVIdoc Gel Documentation System, UK 
Biorad, UV-Transilluminator 2000, USA 
Ice Machine:  
Scotsman Inc., AF20, USA 
Incubator:  
Memmert, Modell 300, GERMANY 
Memmert, Modell 600, GERMANY 
Laminar Flow: Kendro Lab. Prod., Heraeus, HeraSafe HS12, GERMANY 
Magnetic Stirrer:  
VELP Scientifica, ARE Heating Magnetic Stirrer, ITALY 
VELP Scientifica, Microstirrer, ITALY 
Microliter Pipette:  
Gilson, Pipetman, FRANCE 
Mettler Toledo, Volumate, USA 
Microwave Oven:  
Bosch, TÜRKĐYE 
pH meter:  
WTW, pH540 GLP MultiCal®, GERMANY 
Power Supply:  
Biorad, PowerPac 300, USA 
Wealtec, Elite 300, USA 
Refrigerator:  
+4o C, Bosch, TÜRKOYE 
Shaker:  
Forma Scientific, Orbital Shaker 4520, USA 
GFL, Shaker 3011, USA 
New Brunswick Sci., Innova™ 4330, USA 
C25HC Incubator shaker New Brunswick Scientific, USA 
Sonicator Vibracell 75043, Bioblock Scientific,FRANCE 
Spectrophotometer:  
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Schimadzu, UV-1208, JAPAN 
Schimadzu, UV-3150, JAPAN 
Secoman, Anthelie Advanced, ITALY 
Speed Vacuum:  
Savant, Speed Vac® Plus Sc100A, USA 
Savant, Refrigerated Vapor Trap RVT 400, USA 
Thermocycler:  
Eppendorf, Mastercycler Gradient, GERMANY 
Vacuum: 
 Heto, MasterJet Sue 300Q, DENMARK 
Water bath:  
Huber, Polystat cc1, GERMANY 
 
 
 
